Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial

被引：0
|
作者：
Mease, Philip J. [1 ,2 ]
Kavanaugh, Arthur [3 ]
Reimold, Andreas [4 ,5 ]
Tahir, Hasan [6 ]
Rech, Juergen [7 ]
Hall, Stephen [8 ]
Geusens, Piet [9 ,10 ]
Pascale, Pellet [11 ]
Delicha, Evie Maria [11 ]
Pricop, Luminita [12 ]
Mpofu, Shephard [11 ]
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] UC San Diego Sch Med, La Jolla, CA USA
[4] Dallas VA Med Ctr, Dallas, TX USA
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[6] Barts Hlth NHS Trust, London, England
[7] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany
[8] Monash Univ, Melbourne, Vic, Australia
[9] Univ Hasselt, Hasselt, Belgium
[10] Maastricht Univ Hosp, Maastricht, Netherlands
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
961
引用
收藏
页数：3
相关论文
共 50 条
  • [41] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN CLINICAL AND IMAGING OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL MANIFESTATIONS: RESULTS FROM THE MAXIMISE TRIAL
    Baraliakos, Xenofon
    Gossec, Laure
    Pournara, Effie
    Jeka, Slawomir
    Blanco, Ricardo
    D'Angelo, Salvatore
    Schett, Georg
    Schulz, Barbara
    Rissler, Michael
    Whyms, Dermot
    Perella, Chiara
    Coates, Laura C.
    RHEUMATOLOGY, 2021, 60 : 98 - 98
  • [42] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: THREE-YEAR RESULTS FROM PHASE 3 TRIAL, MEASURE 2
    Tahir, Hasan
    Marzo-Ortega, Helena
    Legerton, Clarence W.
    Sieper, Joachim
    Kivitz, Alan
    Blanco, Ricardo
    Cohen, Martin
    Delicha, Evie Maria
    Rohrer, Susanne
    Richards, Hanno B.
    RHEUMATOLOGY, 2018, 57
  • [43] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 4-YEAR RESULTS FROM THE PHASE 3 TRIAL, MEASURE 2
    Marzo-Ortega, Helena
    Sieper, Joachim
    Kivitz, Alan
    Blanco, Richardo
    Cohen, Martin
    Delicha, Eumorphia-Maria
    Rohrer, Susanne
    Richards, Hanno
    RHEUMATOLOGY, 2019, 58
  • [44] SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 3-YEAR RESULTS FROM PHASE III TRIAL, MEASURE 2
    Marzo-Ortega, H.
    Legerton, C. W.
    Sieper, J.
    Kivitz, A. J.
    Blanco, R.
    Cohen, M.
    Delicha, E. M.
    Rohrer, S.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 345 - 345
  • [45] SUBCUTANEOUS SECUKINUMAB PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
    Mease, Philip
    van der Heijde, Desiree
    Landewe, Robert
    Mpofu, Shephard
    Rahman, Proton
    Tahir, Hasan
    Singhal, Atul
    Boettcher, Elke
    Navarra, Sandra
    Zhu, Xuan
    Readie, Aimee
    Abrams, Ken
    Pricop, Luminita
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S10 - S10
  • [46] Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study
    Mease, Philip J.
    van der Heijde, Desiree
    Landewe, Robert B. M.
    Mpofu, Shephard
    Rahman, Proton
    Tahir, Hasan
    Singhal, Atul
    Bottcher, Elke
    Navarra, Sandra V.
    Zhu, Xuan
    Readie, Aimee
    Pricop, Luminita
    Abrams, Ken
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [47] Secukinumab 150 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
    Marzo-Ortega, Helena
    Sieper, Joachim
    Kivitz, Alan J.
    Blanco, Ricardo
    Cohen, Martin
    Delicha, Evie Maria
    Rohrer, Susanne
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [48] Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study
    Kivitz, Alan
    Sedova, Liliana
    Churchill, Melvin
    Kotha, Roshan
    Singhal, Atul
    Torres, Alexander
    Valenzuela, Guillermo
    Whelan, Sarah
    Dumortier, Thomas
    Zhu, Xuan
    Martin, Ruvie
    Pricop, Luminita
    ARTHRITIS & RHEUMATOLOGY, 2024,
  • [49] Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
    McInnes, Iain B.
    Mease, Philip J.
    Ritchlin, Christopher T.
    Rahman, Proton
    Gottlieb, Alice B.
    Kirkham, Bruce
    Kajekar, Radhika
    Delicha, Eumorphia-Maria
    Pricop, Luminita
    Mpofu, Shephard
    RHEUMATOLOGY, 2017, 56 (11) : 1993 - 2003
  • [50] Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
    Marzo-Ortega, H.
    Sieper, J.
    Kivitz, A.
    Blanco, R.
    Cohen, M.
    Martin, R.
    Readie, A.
    Richards, H. B.
    Porter, B.
    ARTHRITIS CARE & RESEARCH, 2017, 69 (07) : 1020 - 1029
12345